SCHEMBL16611174

SCHEMBL16611174

CC(C)(C)OC(=O)N/N=C1\CCCC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MIF P14174 1/20 0.35
▸ MAPT P10636 6/20 0.35
▸ RAB9A P51151 10/20 0.35
▸ NPC1 O15118 7/20 0.35
▸ SMN1; SMN2 Q16637 4/20 0.35
▸ RECQL P46063 1/20 0.35
▸ KDM4E B2RXH2 5/20 0.35
▸ GAA P10253 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HPGD P15428 2/20 0.33
▸ LMNA P02545 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ CASP7 P55210 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16611176 1.00 ALDH1A1 (0.45) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL27123321 0.85 ALDH1A1 (0.45) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL27120428 0.79 KMT2A (0.40) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL29399414 0.78 KMT2A (0.42) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL20583542 0.75 ALDH1A1 (0.57) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL24008102 0.75 KMT2A (0.44) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL16121924 0.74 ALDH1A1 (0.56) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL20533552 0.74 ALDH1A1 (0.56) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL272269 0.74 ALDH1A1 (0.63) ALDH1A1KMT2AMIFMAPTRAB9A
SCHEMBL573354 0.74 ALDH1A1 (0.63) ALDH1A1KMT2AMIFRAB9ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 — — US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 — — US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 — — US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ALDH1A1 3511/4885KMT2A 105/4885MIF 599/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 ALDH1A1 3511/4885KMT2A 105/4885MIF 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback